INIS
patients
100%
tyrosine
91%
kinases
91%
myeloid leukemia
63%
risks
61%
comparative evaluations
36%
in vitro
35%
reviews
34%
covid-19
34%
humans
34%
proteins
32%
biological markers
29%
thrombin
28%
concentration
27%
plasma
24%
nanopowders
22%
inflammation
20%
data
19%
wounds
18%
atherosclerosis
17%
sensitivity
17%
assessments
17%
women
16%
blood
16%
investigations
16%
performance
15%
steroids
15%
drugs
14%
electrochemistry
13%
aggregation
13%
matrices
13%
hemolysis
13%
thrombosis
13%
standardization
13%
doses
13%
neutrophils
12%
molecules
12%
cytokines
11%
copper oxides
11%
interlaboratory comparisons
11%
shells
11%
ruptures
11%
dexamethasone
11%
nucleosomes
11%
validation
11%
metabolites
11%
immunoglobulins
11%
detection
11%
safety
11%
applications
10%
Medicine and Dentistry
Tyrosine-Kinase Inhibitor
34%
Chronic Myelogenous Leukemia
24%
In Vitro
22%
Endothelial Cell
22%
Dasatinib
18%
Ponatinib
15%
Thrombin
14%
Nilotinib
12%
Artery Thrombosis
12%
Activated Protein C Resistance
11%
Biological Marker
11%
Cell Survival
11%
Cell Function
11%
Contraceptive Agent
11%
Disseminated Intravascular Coagulation
11%
Thrombosis
11%
Procoagulant
11%
Acute Leukemia
11%
Immunoglobulin M
11%
Immunoglobulin G
11%
Meta-Analysis
11%
Systematic Review
11%
Imatinib
10%
APC
6%
Independent Reviewer
5%
Keyphrases
Coagulation Properties
11%
Major Molecular Response
11%
Chronic Myeloid Leukemia
11%
Efficacy Biomarkers
11%
BCR-ABL Inhibitors
11%
Cytokine Response
11%
Antifungal Properties
11%
Oxide Nanopowders
11%
Wound Dressing
11%
Human Blood
11%
COVID-19 Shocks
11%
Atherosclerosis Plaque
11%
Critical COVID-19
11%
Plaque Rupture
11%
Safety Profile
11%
Vascular Safety
11%
Regulatory Needs
11%
Unmet Medical Need
11%
Contraceptives
11%
Clinical Investigation
11%
Leukemia Patients
11%
Resistance Test
11%
Inorganic Nanotubes
11%
Arterial Events
8%
Vascular Occlusive Events
8%
Surrogate Biomarkers
5%
Cuprite
5%